Letrozole induction of ovulation in clomiphene citrate resistant polycystic ovary syndrome: responders and non-responders

Size: px
Start display at page:

Download "Letrozole induction of ovulation in clomiphene citrate resistant polycystic ovary syndrome: responders and non-responders"

Transcription

1 Middle East Fertility Society Journal Vol. 9, No. 2, 2004 Copyright Middle East Fertility Society Letrozole induction of ovulation in clomiphene citrate resistant polycystic ovary syndrome: responders and non-responders Aboubakr Elnashar, M.D. Hany Fouad, M.D. Magdy Eldosoky, M.D. Naser Abelgafar, M.S. Benha University Hospital Clinic, Benha, Egypt. ABSTRACT Objective: To evaluate the efficacy of Letrozole in induction of ovulation in cases of CC-resistant PCOS and to compare between Letrozole responders and non-responders. Design: Prospective trial in infertility patients treated with CC Setting: Benha University Hospital Clinic, Egypt. Patient(s): Forty-four infertile women with anovulatory PCOS who failed to ovulate with CC. Intervention(s): Letrozole was given in a dose of 2.5 mg/day from day 3 to day 7 of the menstrual cycle. When the dominant follicle reached a diameter > 18 mm, HCG U was given and timed intercourse was advised. Main outcome measure(s): Occurrence of ovulation, endomertial thickness, cervical score & pregnancy rate Results: On the day of HCG administration, the mean number of follicles 18mm was 1.21, the mean endometrial thickness was 10.2 mm and cervical mucus score was Ovulation occurred in 24 cases (54.6%) and pregnancy in 6 cases (25%). There was no significant difference between Letrozole responders and non-responders as regards the age, period of infertility, BMI, waist circumference, LH, FS H or LH/FSH ratio. Conclusion(s): Induction of ovulation with Letrozole in CC-resistant PCOS is not dependent on age, period of infertility, BMI, waist circumference, menstrual pattern, hirsutism, LH, FSH or LH/FSH ratio. Further studies are necessary to confirm these results. Key Words: Letrozole, clomiphene citrate, PCOS, ovulation, infertility Clomiphene citrate (CC) is the traditional firstline treatment for the chronic anovulation that characterizes PCOS (1). CC is accumulated in the body with low clearance rate and long half-life (5 days). Significant plasma concentrations of the active zu isomer of CC can be detected up to 6 weeks after administration. However, 20-25% of PCOS women fail to ovulate with incremental doses of CC, in addition clinical data revealed a discrepancy between ovulation rates (75-80%) and conception rates (30-40%) during CC treatment (2). Reprint requests: Aboubakr Elnashar, M.D., 24 Gomhoria st., Mansoura, Egypt. Fax: , elnashar53@hotmail.com For these patients, there are a few limited adjunctive therapies that can be tried before moving on to gonadotropin therapy or laparoscopic ovarian drilling including; bromocriptine (in the presence of hyperpolactinemia or galactorrhea), dexamethasone (to reduce adrenal androgen production), insulin sensitizers (to treat hyperinsulinemia), oral contraceptives (for pretreatment suppression of LH), pulsatile GnRH (to preserve physiologic interactive feedback) and extended doses of CC (3). However, their usefulness is limited to specific abnormalities, as many women with CC-failure do not present with any overt signs of a treatable disorder (4). Vol. 9, No. 2, 2004 Elnashar et al. Letrozole for CC-resistant PCOS patients 157

2 Table 1. Clinical and hormonal characteristics of the patients Variable Range Mean ±SD Median 1-Age (years) ± Period of infertility (years) ± Body mass index (kg/m2) ± Waist (cm) ± Waist/Hip ratio ± Menstrual pattern: Oligomenorrhea (number) 31 (71%) Amenorrhea (number) 13 (29%) 7-Hirsutism (number) 28 (64%) 8-LH (U/ml) ± FSH (U/ml) ± LH/FSH ratio ± Mitwally and Casper had reported the novel use of the aromatase inhibitor Letrozole for inducing ovulation in anovulatory women with PCOS and for augmenting ovulation in ovulatory infertile women (1). Letrozole belongs to a new group of very potent, non-steroidal aromatase inhibitor that is rapidly absorbed from the gastrointestinal tract and excreted by the kidney. The elimination halflife of Letrozole is about 2 days (5). Our objective was to evaluate the efficacy of Letrozole in induction of ovulation in cases of CC-resistant PCOS and to compare between Letrozole responders and non-responders. MATERIALS AND METHODS Forty-four infertile women were selected from the patients attending the outpatient clinic of Benha University Hospital. All patients were diagnosed as having anovulation due to PCOS. PCOS was diagnosed when the ultrasonographic findings of PCOS (>10 cysts, 2-8mm in diameter scattered either around or through an echodense, thickened central stroma) are present plus one or more of the following: oligo/amenorrhea with positive progesterone withdrawal bleeding, hirsutism/acne, obesity, raised LH/FSH ratio >2, or raised circulating androgens (Balen, 1999). All patients had previously received CC and diagnosed as having CC-failure (failure of ovulation after 6 cycles of CC reaching the dose of 150 mg daily) (3). Our inclusion criteria:1- Age: between years. 2- Period of infertility > 2 years. 3- Serum level of FSH <12 U/L and serum prolactin level were within normal limits in the early follicular phase. Exclusion criteria were history of pelvic surgery or infertility factor other than anovulation. Hirsutism was diagnosed when the Ferriman & Gallwey score is >8 (3). A two-month washout period before the Letrozole treatment cycle was used to eliminate any post-treatment effect of CC. Patients were examined generally, abdominally and locally. Weight, height, waist and hip circumferences were measured. A transvaginal ultrasound examination was performed to exclude any pelvic pathology before treatment with Letrozole. Ultrasonography was performed using Medison Scan, Sonoace 5500 with a transvaginal transducer 6.5MHz (Medison, Korea). In all patients, Letrozole (Femara; Novartis, East Hanover, NJ) was given orally in a dose of 2.5 mg/day for 5 days starting from the third day of a spontaneous or progesterone induced menstrual bleeding (6). Ovarian follicular response was monitored by transvaginal sonography starting on the next day after finishing Letrozole and thereafter according to the growth of the follicles (usually every other day). Good response was achieved when at least one mature follicle becomes > 18 mm in diameter (Speroff et al, 1999). When the optimal follicle size was reached the endometrial thickness and cervical mucus score 158 Elnashar et al. Letrozole for CC-resistant PCOS patients MEFSJ

3 Table 2. Characteristics of the Letrozole treatment cycles in responders Variable Range Mean±SD Median Day of HCG administration ± No. of days between completion of treatment with Letrozole and follicular maturity ±1.8 6 (Letrozole-free period) On the day of HCG: -No. of follicles 18mm ± Size of follicles 18mm ± Endometrial thickness (mm) ± Cervical mucus score ± were assessed and HCG U (Pregnyl; Organon, Holland) was given intramuscular and timed intercourse was advised. Endometrial thickness was assessed according to Gonen and Casper (7). Cervical mucus score was evaluated for each responding patient at the day of HCG administration. An evaluation of the cervical mucus was calculated according to Moghissi (8). Cervical mucus score was considered good if > 10. Two days after giving HCG, the patients were assessed for ultrasonographic signs of ovulation. Clinical pregnancy was defined as the detection of at least one gestational sac on transvaginal ultrasound examination starting one week after the missed period. Results of Letrozole treatment cycles were described as means ± SD, range and median of each variable. A group t-test was used for comparing two means and Chi-Square test to compare proportion. follicular maturity (Letrozole-free period) was 6.2±1.8 days. On the day of HCG administration; the mean number of follicles> or = 18 mm was 1.21±0.86 (range, 1-2) distributed as follows; 19 patients had developed 1 follicle each and 5 patients had 2 follicles each. Letrozole was very well tolerated as no patients complained of any side effect. During Letrozole treatment, ovulation occurred in 24 cases (54.6%) and clinical pregnancy in 6 cases (25%). These pregnancies were single and resulted from timed intercourse in 6 couples; 4 of them developed one follicle each and two couples developed 2 follicles each. There were neither abortions nor multiple pregnancies. Table 3 shows the clinical characteristics of both Letrozole-responders and non-responders, there was insignificant difference between both groups as regards age, period of infertility, BMI, waist circumference, W/H ratio, LH, FSH and LH/FSH ratio. RESULTS Table 1 shows demographic, clinical and hormonal features of all women involved in this study. All patients were either overweight or obese with a mean BMI, 29.61±3.35 Kg/m2 (range ) with android obesity as indicated by waist circumference (mean 99.9±8.98 cm) and waist/hip ratio (mean= 0.98± 0.04). Table 2 shows the characteristics of the Letrozole treatment cycles where each patient had received one letrozole treatment cycle. The number of days between completion of treatment with Letrozole and DISCUSSION A simple, inexpensive and safe alternative to CC that can cover the goal of ovulation induction to induce monofollicular development and subsequent ovulation is needed. In this study, the mean (±SD) day of HCG administration was 13.2±1.76 and this agrees with the results of Mitwally and Casper, as it was 14.2±2.1 (1). In this study, the mean (±SD) number of days between completion of treatment with Letrozole and the day of HCG administration was 6.2±1.8 days. Letrozole has a short half-life (around 2 days) Vol. 9, No. 2, 2004 Elnashar et al. Letrozole for CC-resistant PCOS patients 159

4 Table 3. Clinical characteristics of both Letrozole responders and Letrozole non-responders. Variable Responders (n=24) Non-Responders (n=20) Significance 1-Age(years) 26.7± ±4.36 NS (a) 2-Period of infertility(y) 4.56± ±2.29 NS (a) 3-BMI (kgm/m2) 30.07± ±3.59 NS (a) 4-Waist (cm) 99± ±8.41 Ns (a) 5-W/H ratio 0.89± ±0.04 NS (a) 6-Menstrual pattern: Oligomenorrhea: No(%) 16 (66.66%) 14 (70%) NS (b) Amenorrhea: No (%) 8 (33.33%) 6 (30%) NS (b) 7-Hirsutism: No(%) 15 (62.5%) 13 (65%) NS (b) 6-LH (IU/ml) 16.7± ±3.65 NS (a) 7-FSH (IU/ml) 6.5± ±1.81 NS (a) 8-LH/FSH ratio 2.68± ±0.45 NS (a) NS= not significant. Variables are measured by mean ±SD P value = 0.05 (a) t test (b) X 2 tests leading to lower negligible levels of Letrozole in the body around the time of ovulation and early embryogenesis period (5). Letrozole was very well tolerated as no patients complained of any side effects. Because of the tolerability of Letrozole and its short half-life, Letrozole has been used as a single dose of 20mg on the third day of the menstrual cycle to ensure low levels around the time of ovulation without any side effects (9). In this study, the mean number of mature follicles 18 mm on the day of HCG administration was 1.21 (range 1-2) where 19 patients (79%) developed one mature follicle and 5 patients (21%) developed 2 mature follicles. This limited number of mature follicles (range 1-2) with Letrozole will decrease the risk of multiple pregnancy and ovarian hyperstimulation syndrome (OHSS). These results are in agreement with the results of Al-Omari et al (10) and Mitwally and Casper (5) Therefore, Letrozole treatment does not need intensive monitoring compared to CC and gonadotropins. In this study, the mean endometrial thickness on the day of HCG administration was 10.2±1.31 mm. Thus the endometrium was of adequate thickness to allow implantation. Letrozole induces ovulation but without estrogen receptors downregulation. The adverse endometrial effect seen with CC, which is augmented by the relatively long half-life of CC (5 days), are not seen with Letrozole. This result is consistent with the results of other studies; in this study, the mean cervical mucus score was 11.42±2.48 according to the criteria of Moghissi (8). He considered a cervical mucus score of > 10 is a good one while a score of <10 is a poor one. This result indicates that, Letrozole has no adverse antiestrogenic effect on the cervical mucus. This result is consistent with the results of Metawie (11) Poor mucus at midcycle can be a physical barrier that decreases sperm penetration. In this study, ovulation occurred in 24 cases (54.6%). Administration of Letrozole in the early part of the menstrual cycle, would release the pituitary/hypothalamic axis from the estrogenic negative feedback, similar to the effect of CC but without estrogen receptors down-regulation, and the resulting increase in gonadotropin secretion could stimulate ovarian follicle development (1). Also, Letrozole may act locally in the ovary to increase the follicular sensitivity to FSH by increasing the local androgen in the ovary because conversion of androgen substrate to estrogen is blocked. The ovulation rate in this study is lower than that obtained by other studies using Letrozole in ovulation induction. Mitwally and Casper (5) had ovulatory rates of 75%, Al-Omari et al (10) had an ovulatory rate of 87.5% and Metawie (11) had a 160 Elnashar et al. Letrozole for CC-resistant PCOS patients MEFSJ

5 rate of 92.5%. However, the variable results can be explained by the smaller numbers of the patients of other studies; in our study, we administered Letrozole for only one cycle (i.e. ovulatory rate per cycle), while the 22 patients in Al-Omari study received Letrozole for 32 treatment cycles from the second day of the menstrual cycle (10). Metawie started Letrozole in a dose of 5mg/day for 5 days (11). In this study, pregnancy occurred in 6 patients; thus the percent of pregnancies per induced ovulatory cycle is 25%. This result is comparable with the results of Mitwally and Casper (25%), Al- Omari et al (27.27%) and Metawie (17.5%) (5,10,11). All these pregnancies were single, which is consistent with the results of other studies. This may be due to the limited number of mature follicles (range 1-2). Compared to other methods of ovulation induction, the multiple pregnancy rate is approximately 10% with CC, almost entirely twins (12), about 15-25% with gonadotropins (13) and about 2 % with laparoscopic ovarian drilling (14). Compared to laparoscopic ovarian drilling, there is no risk of operative interference as the anesthetic risk, adhesion formation and the possibility of ovarian destruction and premature ovarian failure (15). Comparing both groups of Letrozole responders and non-responders as regards clinical and laboratory characteristics we found that, there were no significant differences as regards BMI, waist circumference and W/H ratio, hirsutism, LH, FSH and LH/FSH ratio. Thus we can give Letrozole to all patients with CC-resistance, as its efficacy is not limited to a specific abnormality. So it can be used whatever the BMI. Achieving weight reduction is extremely difficult, particularly as the metabolic status of patients with PCOS conspires against weight loss (16). Also, Letrozole can be used with good results in patients with hirsutism and there is no need to add dexamethasone to reduce adrenal androgen production. Dexamethasone can worsen diabetic tendencies because of its effect on blood sugar and as a result, it may not be a suitable treatment for patients with diabetes, insulin resistant or glucose intolerance, conditions present in many PCOS patients (3). Also from these results, Letrozole can be used in case of high LH without the need to add oral contraceptives for pretreatment suppression of LH. Oral contraceptive pills exacerbate insulin resistance and since many patients are overweight and obesity is a relative contraindication, this treatment may be unsuitable (17). Also, there is a doubt about the short and long term safety of ovarian suppression in polycystic ovary with oral contraceptives (18). In conclusion; induction of ovulation with Letrozole in CC-failure PCOS is associated with limited number of mature follicles, no adverse effect on endometrium or cervix, ovulation and pregnancy in a significant number of patients. Induction with Letrozole is not dependent on age, period of infertility, BMI, waist circumference, LH, FSH or LH/FSH ratio. Further studies are necessary to confirm our results. REFERENCES 1. Lidor AL, Goldenberg M, Cohen SB, Seidman DS, Mashiach S, Rabinovici J. Management of women with polycystic ovary syndrome who experienced premature luteinization during clomiphene citrate treatment. Fertil Steril 2000;74: Yen SS. chronic anovulation caused by peripheral endocrine disorders. In: Yen SS, Jaffe RB, eds. Reproductive endocrinology: physiology, pathophysiology, and clinical management, 3rd ed Philadelphia: Saunders:1991: Speroff L, Glass RH, Kase NG. Hormone biosynthesis, metabolism, and mechanism of action. In: Clinical gynecologic endocrinology and infertility. Baltimore, Lippincott, Williams & Wilkins, 6th Ed, 1999,31-105; ; Branigan ME, Estes A. Using oral contraceptives as a treatment for clomid-resistant patients. Fertil Steril 1999;71: Mitwally FM and Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 2001;75: Femara (Letrozole) package insert. Novartis Pharmaceuticals Corporation, East Hanover, NJ Gonen Y, Casper RF. Sonographic determination of an adverse effect of clomiphene citrate on endometrial growth. Hum Reprod 1990;5: Moghissi KS. Postcoital test, physiologic basis, technique and interpretation. Fertil Steril 1976;27: Mitwally MF, Casper RF. Single dose administration of the aromatase inhibitor, Letrozole: a simple and convenient effective method of ovulation induction. Fertil Steril 2001;76:S94-5. Vol. 9, No. 2, 2004 Elnashar et al. Letrozole for CC-resistant PCOS patients 161

6 10. Al-Omari W, Al-Hadithi N, Izat B, Sulaiman W. The effect of an aromatase inhibitor on ovulation induction and endometrial receptivity in clomiphene resistant women with polycystic ovary syndrome. Mid East Fertil Soc J 2001;6:S Metawie MH. Comparative study of aromatase inhibitor, Letrozole, with clomiphene citrate for induction of ovulation. Mid East Fertil Soc J 2001;6:S Kousta E, White DM, Franks S. Modern use of clomiphene citrate in induction of ovulation. Hum Reprod Update 1997;3: March CM. Human menopausal gonadotropins. Infertil Reprod Med Clin North Am 1990;1: Felemban A, Tan SL, Tulandi T. Laparoscopic treatment of polycystic ovary syndrome with insulated needle cautery, a reappraisal. Fertil Steril 2000:73: Balen AH, Jacobs HS. A prospective study comparing unilateral and bilateral laparoscopic ovarian diathermy in women with the polycystic ovary syndrome. Fertil Steril 1994;62: Kim LH, Taylor AE, Barbieri RL. Insulin sensitizers and polycystic ovary syndrome: can a diabetes medication treat infertility? Fertil Steril 2000:73; Sheu WH, Hsu CH, Chen YS, Jeng CY, Fuh MM. Prospective evaluation of insulin resistance and lipid metabolism in women receiving the oral contraceptive. Clin Endocrinol 1994;40: Nader S, Riad-Gabriel M, Saad M. The effect of a desogestrel-containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women. J Clin Endocrinol Metab 1997;82: Received on December 14, 2003; revised and accepted on March 1, Elnashar et al. Letrozole for CC-resistant PCOS patients MEFSJ

POLYCYSTIC OVARY SYNDROME

POLYCYSTIC OVARY SYNDROME POLYCYSTIC OVARY SYNDROME Information Leaflet Your Health. Our Priority. Page 2 of 6 What is polycystic ovary syndrome? (PCOS) Polycystic ovary syndrome (PCOS) is the most common hormonal disorder in women

More information

HEALTH UPDATE. Polycystic Ovary Syndrome (PCOS)

HEALTH UPDATE. Polycystic Ovary Syndrome (PCOS) HEALTH UPDATE PO Box 800760 Charlottesville, VA 22908 Gynecology: (434) 924-2773 Polycystic Ovary Syndrome (PCOS) What is it? An endocrine (hormonal) disorder. Because there is such variability in how

More information

INFERTILITY/POLYCYSTIC OVARIAN SYNDROME. Ovulatory Dysfunction: Polycystic ovarian syndrome (PCOS)

INFERTILITY/POLYCYSTIC OVARIAN SYNDROME. Ovulatory Dysfunction: Polycystic ovarian syndrome (PCOS) Introduction Infertility is defined as the absence of pregnancy following 12 months of unprotected intercourse. Infertility may be caused by Ovulatory Dysfunction, Blocked Fallopian Tubes, Male Factor

More information

Polycystic Ovarian Syndrome

Polycystic Ovarian Syndrome Polycystic Ovarian Syndrome What is Polycystic Ovarian Syndrome? Polycystic ovary syndrome (or PCOS) is a common condition affecting 3 to 5% of women of reproductive age. It is linked with hormonal imbalances,

More information

Emmett F. Branigan, MD,* Antoinette Estes, BS, Kenneth Walker, BS, Jillian Rothgeb, BS. Bellingham IVF and Infertility Center, Bellingham, WA

Emmett F. Branigan, MD,* Antoinette Estes, BS, Kenneth Walker, BS, Jillian Rothgeb, BS. Bellingham IVF and Infertility Center, Bellingham, WA American Journal of Obstetrics and Gynecology (2006) 194, 1696 701 www.ajog.org Thorough sonographic oocyte retrieval during in vitro fertilization produces results similar to ovarian wedge resection in

More information

INSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME

INSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME 1 University of Papua New Guinea School of Medicine and Health Sciences Division of Basic Medical Sciences Discipline of Biochemistry and Molecular Biology PBL SEMINAR INSULIN RESISTANCE, POLYCYSTIC OVARIAN

More information

Medications for Inducing Ovulation

Medications for Inducing Ovulation AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE Medications for Inducing Ovulation A Guide for Patients PATIENT INFORMATION SERIES Published by the American Society for Reproductive Medicine under the direction

More information

FACT SHEET. The Polycystic Ovary Syndrome (PCOS) Introduction

FACT SHEET. The Polycystic Ovary Syndrome (PCOS) Introduction FACT SHEET The Polycystic Ovary Syndrome (PCOS) Introduction The polycystic ovary syndrome (PCOS) is the commonest hormonal disturbance to affect women. The main problems that women with PCOS experience

More information

Polycystic Ovary Syndrome

Polycystic Ovary Syndrome Polycystic Ovary Syndrome Polycystic ovary syndrome (PCOS) is a disorder that affects as many as 5 10% of women. PCOS has three key features: 1) high levels of hormones called androgens; 2) irregular menstrual

More information

Drug Therapy Guidelines: Injectable Fertility Medications

Drug Therapy Guidelines: Injectable Fertility Medications Drug Therapy Guidelines: Injectable Fertility Medications Effective Date: 11/20/07 Committee Review Date: 7/12/00, 5/8/01, 1/15/02, 5/6/0, 12/16/0, 6/8/04, 12/16/05, 2/1/06, 10/15/06, 7/20/07, 11/5/07

More information

Anatomy and Physiology of Human Reproduction. Module 10a

Anatomy and Physiology of Human Reproduction. Module 10a This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this

More information

From Menses to Menopause: How Hormones Can Affect Blood Glucose Levels. Christine Day, RN, MS, CNS-BC Lake Superior College

From Menses to Menopause: How Hormones Can Affect Blood Glucose Levels. Christine Day, RN, MS, CNS-BC Lake Superior College From Menses to Menopause: How Hormones Can Affect Blood Glucose Levels Christine Day, RN, MS, CNS-BC Lake Superior College Overview Will review hormonal changes over the female lifespan Discuss the effects

More information

Polycystic Ovarian Syndrome (PCOS)

Polycystic Ovarian Syndrome (PCOS) UW MEDICINE PATIENT EDUCATION Polycystic Ovarian Syndrome (PCOS) Signs, symptoms, and treatments What is PCOS? Polycystic ovarian syndrome (PCOS) is a disorder that affects up to 1 in 10 women of reproductive

More information

Polycystic ovary syndrome (PCOS)

Polycystic ovary syndrome (PCOS) Centre for Diabetes and Endocrinology - Patient information Polycystic ovary syndrome (PCOS) Approximately 1 in 5 women have polycystic ovaries. This describes the appearance of the ovaries when they are

More information

Saudi Med J 2007; Vol. 28 (7): 1039-1043

Saudi Med J 2007; Vol. 28 (7): 1039-1043 Free testosterone, luteinizing hormone/follicle stimulating hormone ratio and pelvic sonography in relation to skin manifestations in patients with polycystic ovary syndrome Khalifa E. Sharquie, MD, PhD,

More information

EFFECT OF INCREASED TESTOSTERONE LEVEL ON WOMAN S FERTILITY

EFFECT OF INCREASED TESTOSTERONE LEVEL ON WOMAN S FERTILITY 1 Nada Polyclinic, Po ega, Croatia 2 School of Medicine, University of Zagreb, Zagreb, Croatia Preliminary Communication Received: April 15, 2004 Accepted: June 16, 2004 EFFECT OF INCREASED TESTOSTERONE

More information

Medications for Inducing Ovulation

Medications for Inducing Ovulation AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE Medications for Inducing Ovulation A Guide for Patients PATIENT INFORMATION SERIES Published by the American Society for Reproductive Medicine under the direction

More information

Welcome to chapter 8. The following chapter is called "Monitoring IVF Cycle & Oocyte Retrieval". The author is Professor Jie Qiao.

Welcome to chapter 8. The following chapter is called Monitoring IVF Cycle & Oocyte Retrieval. The author is Professor Jie Qiao. Welcome to chapter 8. The following chapter is called "Monitoring IVF Cycle & Oocyte Retrieval". The author is Professor Jie Qiao. The learning objectives of this chapter are 2 fold. The first section

More information

Subject Index. Bariatric surgery, obesity management 134

Subject Index. Bariatric surgery, obesity management 134 Subject Index Acromegaly, PCOS differential diagnosis 149, 150, 154, 155 Adipokines, see specific adipokines Adiponectin, metabolic syndrome role 41 43 Adolescents, PCOS diagnosis 16, 17 Adrenal hyperplasia,

More information

The Menstrual Cycle. Model 1: Ovarian Cycle follicular cells

The Menstrual Cycle. Model 1: Ovarian Cycle follicular cells The Menstrual Cycle REVIEW questions to complete before starting this POGIL activity 1. Gonads produce both gametes and sex steroid hormones. For the female, name the: A. gonads ovaries B. gametes oocyte/ovum/egg

More information

CYCLE EVALUATION. Please review this guide carefully. I. Early In Cycle. A. Selection of the Dominant Follicle (~ Day 3)

CYCLE EVALUATION. Please review this guide carefully. I. Early In Cycle. A. Selection of the Dominant Follicle (~ Day 3) CYCLE EVALUATION In order to evaluate how well you ovulate, we will see you on three days during your menstrual cycle. Early in the cycle you select a dominant follicle, on or about the third day of your

More information

Endocrinology of the Female Reproductive Axis

Endocrinology of the Female Reproductive Axis Endocrinology of the Female Reproductive Axis girlontheriver.com Geralyn Lambert-Messerlian, PhD, FACB Professor Women and Infants Hospital Alpert Medical School at Brown University Women & Infants BROWN

More information

Polycystic ovary syndrome: what it means for your long-term health

Polycystic ovary syndrome: what it means for your long-term health Polycystic ovary syndrome: what it means for your long-term health Information for you Published in February 2005, minor amendments in June 2005 Revised 2009 What is polycystic ovary syndrome? Polycystic

More information

Research Article Association of ABO Blood Type and Ovarian Stimulation Response in Oocyte Donors

Research Article Association of ABO Blood Type and Ovarian Stimulation Response in Oocyte Donors Cronicon OPEN ACCESS Nigel Pereira 1 *, Anne P Hutchinson 2, Jovana P Lekovich 1, Rony T Elias 1, Zev Rosenwaks 1 and Steven D Spandorfer 1 1 Ronald O Perelman and Claudia Cohen Center for Reproductive

More information

Eastern Mediterranean Health Journal, Vol. 10, No. 3, 2004 437

Eastern Mediterranean Health Journal, Vol. 10, No. 3, 2004 437 Eastern Mediterranean Health Journal, Vol. 10, No. 3, 2004 437 Report Normal uterine size in women of reproductive age in northern Islamic Republic of Iran S. Esmaelzadeh, 1 N. Rezaei 1 and M. HajiAhmadi

More information

Elevated serum progesterone on the day of HCG administration in IVF is associated with a higher pregnancy rate in polycystic ovary syndrome

Elevated serum progesterone on the day of HCG administration in IVF is associated with a higher pregnancy rate in polycystic ovary syndrome Human Reproduction vol.14 no.3 pp.601 605, 1999 Elevated serum progesterone on the day of HCG administration in IVF is associated with a higher pregnancy rate in polycystic ovary syndrome Nicola Doldi

More information

How do fertility drugs work?

How do fertility drugs work? How do fertility drugs work? Under normal circumstances, ovulation occurs once a month when a ripened egg which is ready to be fertilised is released from the ovaries. For couples who are trying to conceive,

More information

Abigail R. Proffer, M.D. October 4, 2013

Abigail R. Proffer, M.D. October 4, 2013 Abigail R. Proffer, M.D. October 4, 2013 Topics Human Papillomavirus (HPV) Vaccines Pap smears Colposcopy Contraception Polycystic Ovary Syndrome (PCOS) Can I get pregnant? Miscarriage Abnormal Uterine

More information

Clinical Study Comparison of Endocrine Profile and In Vitro Fertilization Outcome in Patients with PCOS, Ovulatory PCO, or Normal Ovaries

Clinical Study Comparison of Endocrine Profile and In Vitro Fertilization Outcome in Patients with PCOS, Ovulatory PCO, or Normal Ovaries International Endocrinology Volume 2012, Article ID 492803, 6 pages doi:10.1155/2012/492803 Clinical Study Comparison of Endocrine Profile and In Vitro Fertilization Outcome in Patients with PCOS, Ovulatory

More information

The objectives of this chapter are: To provide an understanding of the various stimulation protocols used in IVF To enable the student to understand

The objectives of this chapter are: To provide an understanding of the various stimulation protocols used in IVF To enable the student to understand 1 The objectives of this chapter are: To provide an understanding of the various stimulation protocols used in IVF To enable the student to understand the factors affecting the choice of protocol based

More information

Hormonal Oral Contraceptives: An Overview By Kelsie Court. A variety of methods of contraception are currently available, giving men and

Hormonal Oral Contraceptives: An Overview By Kelsie Court. A variety of methods of contraception are currently available, giving men and Hormonal Oral Contraceptives: An Overview By Kelsie Court A variety of methods of contraception are currently available, giving men and women plenty of options in choosing a method suitable to his or her

More information

In Vitro Fertilization

In Vitro Fertilization Patient Education In Vitro Fertilization What to expect This handout describes how to prepare for and what to expect when you have in vitro fertilization. It provides written information about this process,

More information

Hull & East Riding Prescribing Committee

Hull & East Riding Prescribing Committee Hull & East Riding Prescribing Committee Guideline on Prescribing of Gonadorelin (GnRH) Analogues and Progesterone Receptor Modulators in treatment of Endometriosis or prior to Endometrial Ablation, or

More information

Georgia Reproductive Specialists

Georgia Reproductive Specialists Georgia Reproductive Specialists A cost efficient approach to infertility diagnosis and Treatment for the OBGYN generalist Introduction The purpose of this proposal is to outline suggested clinical pathways

More information

The IUI procedure Who should consider an IUI IUI success rates IUI cost What to consider if IUI is unsuccessful. The IUI procedure:

The IUI procedure Who should consider an IUI IUI success rates IUI cost What to consider if IUI is unsuccessful. The IUI procedure: A Complete Guide to understanding IUI (intrauterine insemination) and artificial insemination (Eric Daiter, MD Board Certified in Reproductive Endocrinology and Infertility) The IUI procedure Who should

More information

women and sport Fertility Angelica Lindén Hirschberg

women and sport Fertility Angelica Lindén Hirschberg women and sport SCIENTIFIC REPORT SERIESI issue 2.5 YEAR 2014 Fertility Angelica Lindén Hirschberg PUBLISHED BY SISU sport books IN COOPERATION WITH WORLD VILLAGE OF WOMAN SPORTS FERTILITY Angelica Lindén

More information

Polycystic Ovarian Disease: Treatment Protocols

Polycystic Ovarian Disease: Treatment Protocols October 08, 2011 By Galal Lotfi, MD, MRCOG [1] Stein and Leventhal were the first to recognize an association between the presence of polycystic ovaries and signs of hirsutism, amenorrhea, oligomenorrhea

More information

The Menstrual Cycle, Hormones and Fertility Treatment

The Menstrual Cycle, Hormones and Fertility Treatment The Menstrual Cycle, Hormones and Fertility Treatment How many of us understand how our monthly cycle works? Every 28 days (or thereabouts), between the ages of around 13 and 51, a woman will release a

More information

Artificial insemination with donor sperm

Artificial insemination with donor sperm Artificial insemination with donor sperm Ref. 123 / 2009 Reproductive Medicine Unit Servicio de Medicina de la Reproducción Gran Vía Carlos III 71-75 08028 Barcelona Tel. (+34) 93 227 47 00 Fax. (+34)

More information

Introduction Ovarian cysts are a very common female condition. An ovarian cyst is a fluid-filled sac on an ovary in the female reproductive system.

Introduction Ovarian cysts are a very common female condition. An ovarian cyst is a fluid-filled sac on an ovary in the female reproductive system. Ovarian Cysts Introduction Ovarian cysts are a very common female condition. An ovarian cyst is a fluid-filled sac on an ovary in the female reproductive system. Most women have ovarian cysts sometime

More information

Artificial insemination

Artificial insemination Artificial insemination What is involved? Artificial insemination is an assisted reproduction technique that consists of inserting laboratory-treated spermatozoa into the woman s uterus or cervical canal.

More information

The effect of administration of metformin on lipid profile changes and insulin resistance in patients with polycystic ovary syndrome

The effect of administration of metformin on lipid profile changes and insulin resistance in patients with polycystic ovary syndrome Middle East Fertility Society Journal Vol. 12, No. 3, 2007 Copyright Middle East Fertility Society The effect of administration of metformin on lipid profile changes and insulin resistance in patients

More information

Reduced Ovarian Reserve Is there any hope for a bad egg?

Reduced Ovarian Reserve Is there any hope for a bad egg? Reduced Ovarian Reserve Is there any hope for a bad egg? Dr. Phil Boyle Galway Clinic, 19 th March 2014 For more information on Low AMH see www.napro.ie Anti Mullerian Hormone AMH levels are commonly measured

More information

Hirsutism and Polycystic Ovary Syndrome (PCOS)

Hirsutism and Polycystic Ovary Syndrome (PCOS) AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE Hirsutism and Polycystic Ovary Syndrome (PCOS) A Guide for Patients PATIENT INFORMATION SERIES Published by the American Society for Reproductive Medicine under

More information

Ehlers-Danlos Syndrome Fertility Issues. Objectives

Ehlers-Danlos Syndrome Fertility Issues. Objectives Ehlers-Danlos Syndrome Fertility Issues Baltimore Inner Harbor Independence Day Brad Hurst, M.D. Professor Reproductive Endocrinology Carolinas Medical Center - Charlotte, North Carolina Objectives Determine

More information

The Journal of Integrated Health Sciences

The Journal of Integrated Health Sciences JIHS Available online at www.jihs.in The Journal of Integrated Health Sciences A study of endocrine profile in premenopausal women with hirsutism Lakhani Som J 1*, Lakhani Om J 2, Raval RC 3 1 Assistant

More information

Page 1 of 7 Polycystic Ovary Syndrome (PCOS), Insulin Resistance (IR), & the Metabolic Syndrome

Page 1 of 7 Polycystic Ovary Syndrome (PCOS), Insulin Resistance (IR), & the Metabolic Syndrome Page 1 of 7 Polycystic Ovary Syndrome (PCOS), Insulin Resistance (IR), & the Metabolic Syndrome I. LANE WONG, MD, FACOG. www.hopeivf.com www.hopefertilitycenter.com Polycystic Ovary Syndrome (PCOS), Insulin

More information

In vitro fertilization for Orthodox Jewish couples: antagonist cycle modifications allowing for mikveh attendance before oocyte retrieval

In vitro fertilization for Orthodox Jewish couples: antagonist cycle modifications allowing for mikveh attendance before oocyte retrieval In vitro fertilization for Orthodox Jewish couples: antagonist cycle modifications allowing for mikveh attendance before oocyte retrieval David E. Reichman, M.D., Anate Aelion Brauer, M.D., Dan Goldschlag,

More information

Egg Donation Process, Risks, Consent and Agreement

Egg Donation Process, Risks, Consent and Agreement THE CENTER FOR HUMAN REPRODUCTION (CHR) 21 East 69 th Street, New York, NY 10021 T: 212-994-4400; F: 212-994-4499 Egg Donation Process, Risks, Consent and Agreement Updated on: 10/8/2014 Date: Egg Donor

More information

THE CENTER FOR ADVANCED REPRODUCTIVE SERVICES (CARS) (The Center) CONSENT FOR IN VITRO FERTILIZATION AND EMBRYO TRANSFER

THE CENTER FOR ADVANCED REPRODUCTIVE SERVICES (CARS) (The Center) CONSENT FOR IN VITRO FERTILIZATION AND EMBRYO TRANSFER THE CENTER FOR ADVANCED REPRODUCTIVE SERVICES (CARS) (The Center) CONSENT FOR IN VITRO FERTILIZATION AND EMBRYO TRANSFER Partner #1 Last Name (Surname): Partner #1 First Name: Partner #1 Last 5 Digits

More information

Guidelines for Ordering Serum Levels of Gonadotropins (FSH, LH) and Prolactin CLP 021 Revised June, 2008 (Replaces October 2000 version)

Guidelines for Ordering Serum Levels of Gonadotropins (FSH, LH) and Prolactin CLP 021 Revised June, 2008 (Replaces October 2000 version) Guidelines for Ordering Serum Levels of Gonadotropins (FSH, LH) and Prolactin CLP 021 Revised June, 2008 (Replaces October 2000 version) 1. Scope This laboratory Guideline is intended to assist community

More information

Page 1 of 7 Polycystic Ovary Syndrome (PCOS), Insulin Resistance (IR), & the Metabolic Syndrome

Page 1 of 7 Polycystic Ovary Syndrome (PCOS), Insulin Resistance (IR), & the Metabolic Syndrome Page 1 of 7 Polycystic Ovary Syndrome (PCOS), Insulin Resistance (IR), & the Metabolic Syndrome I. LANE WONG, MD, FACOG. www.hopeivf.com Polycystic Ovary Syndrome (PCOS), Insulin Resistance (IR), Type

More information

Ovarian Cyst. Homoeopathy Clinic. Introduction. Types of Ovarian Cysts. Contents. Case Reports. 21 August 2002

Ovarian Cyst. Homoeopathy Clinic. Introduction. Types of Ovarian Cysts. Contents. Case Reports. 21 August 2002 Case Reports 21 August 2002 Ovarian Cyst Homoeopathy Clinic Check Yourself If you have any of the following symptoms call your doctor. Sense of fullness or pressure or a dull ache in the abdomen Pain during

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT ACEGON, 50 microgram/ml, solution for injection for cattle. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active

More information

1: Chlamydia. Infertility National Public Awareness Campaign. Information Sheet. Female Infertility. What is Chlamydia?

1: Chlamydia. Infertility National Public Awareness Campaign. Information Sheet. Female Infertility. What is Chlamydia? Infertility National Public Awareness Campaign Information Sheet Female Infertility 1: Chlamydia What is Chlamydia? Genital Chlamydia is a bacterium infecting the genital tract, eyes, and throat. It is

More information

Diagnosis and treatment of polycystic ovary syndrome (PCOS): An interview with Richard Legro

Diagnosis and treatment of polycystic ovary syndrome (PCOS): An interview with Richard Legro Legro BMC Medicine (2015) 13:64 DOI 10.1186/s12916-015-0299-2 QUESTION AND ANSWER Diagnosis and treatment of polycystic ovary syndrome (PCOS): An interview with Richard Legro Richard Legro Open Access

More information

Insulin Resistance and PCOS: A not uncommon reproductive disorder

Insulin Resistance and PCOS: A not uncommon reproductive disorder Insulin Resistance and PCOS: A not uncommon reproductive disorder Joyce L. Ross, MSN, CRNP, CS, FNLA, FPCNA Diplomate Accrediation Council for Clinical Lipidology President Preventive Cardiovascular Nurses

More information

OVULATION & INTRAUTERINE INSEMINATION (IUI)

OVULATION & INTRAUTERINE INSEMINATION (IUI) OVULATION & This handbook is intended to give you an overview of infertility treatment with IUI and ovulation induction and to better understand the medical circumstances that lead to this treatment option.

More information

Unit 3 REPRODUCTIVE SYSTEMS AND THE MENSTRUAL CYCLE

Unit 3 REPRODUCTIVE SYSTEMS AND THE MENSTRUAL CYCLE Unit 3 REPRODUCTIVE SYSTEMS AND THE MENSTRUAL CYCLE Learning Objectives By the end of this unit, the learner should be able to: Explain the importance of understanding the male and female reproductive

More information

patientinformation Polycystic ovary syndrome Obstetrics & Gynaecology The Rotherham NHS Foundation Trust

patientinformation Polycystic ovary syndrome Obstetrics & Gynaecology The Rotherham NHS Foundation Trust The Rotherham NHS Foundation Trust Polycystic ovary syndrome Obstetrics & Gynaecology patientinformation Your health, your life, your choice, our passion Hearing about your experience of our services is

More information

Dysfunctional Uterine Bleeding

Dysfunctional Uterine Bleeding :{ic0fp'16 ACOFP 53 rd Annual Convention & Scientific Seminars Dysfunctional Uterine Bleeding Michele Tartaglia, DO Michele Tartaglia, DO, FACOOG, CS Assistant Professor and Residency Program Director

More information

1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME

1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME 1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME Izet Aganović, Tina Dušek Department of Internal Medicine, Division of Endocrinology, University Hospital Center Zagreb, Croatia 1 Introduction The metabolic syndrome

More information

PCOS. What to do about insulin resistance in. Aclearer understanding of. In this article: By R. Hugh Gorwill, MD, FRCSC

PCOS. What to do about insulin resistance in. Aclearer understanding of. In this article: By R. Hugh Gorwill, MD, FRCSC Focus on CME at Queen s University Queen s University What to do about insulin resistance in PCOS By R. Hugh Gorwill, MD, FRCSC In this article: Aclearer understanding of polycystic ovary syndrome (PCOS)

More information

1. AMOUNT OF FSH PRESENT

1. AMOUNT OF FSH PRESENT The Menstrual Cycle Name Date Period PRE-LAB 1. Write down three facts you know about the menstrual cycle. A. B. C. FOLLICULAR PHASE Within the ovaries are located many egg cells. Each egg is enclosed

More information

The ABC s and T s of Male Infertility

The ABC s and T s of Male Infertility The ABC s and T s of Male Infertility Men s Health Initiative of BC - Focus on Testosterone Ethan D. Grober, MD, MEd, FRCSC Assistant Professor University of Toronto Department of Surgery, Division of

More information

POLYCYSTIC OVARY SYNDROME (PCOS), INSULIN RESISTANCE (IR), & METFORMIN: LATEST DEVELOPMENTS

POLYCYSTIC OVARY SYNDROME (PCOS), INSULIN RESISTANCE (IR), & METFORMIN: LATEST DEVELOPMENTS POLYCYSTIC OVARY SYNDROME (PCOS), INSULIN RESISTANCE (IR), & METFORMIN: LATEST DEVELOPMENTS I. Lane Wong, M.D., F.A.C.O.G. Board Certified, Reproductive Endocrinology and Infertility Recently, there has

More information

In - Vitro Fertilization Handbook

In - Vitro Fertilization Handbook In - Vitro Fertilization Handbook William F. Ziegler, D.O. Medical Director Scott Kratka, ELD, TS Embryology Laboratory Director Lauren F. Lucas, P.A.-C, M.S. Physician Assistant Frances Cerniak, R.N.

More information

Fertility care for women diagnosed with cancer

Fertility care for women diagnosed with cancer Saint Mary s Hospital Department of Reproductive Medicine Fertility care for women diagnosed with cancer Information For Patients INF/DRM/NUR/16 V1/01/11/2013 1 2 Contents Page Overview 4 Our Service 4

More information

ACTIVITY DISCLAIMER. Polycystic Ovary Syndrome and Hyperandrogenism

ACTIVITY DISCLAIMER. Polycystic Ovary Syndrome and Hyperandrogenism Polycystic Ovary Syndrome and Hyperandrogenism Lisa G. Soldat, MD, MS, FAAFP ACTIVITY DISCLAIMER The material presented here is being made available by the American Academy of Family Physicians for educational

More information

PACKAGE INSERT PREGNYL. (chorionic gonadotropin for injection, USP) 10,000 units/vial. Human Gonadotropin

PACKAGE INSERT PREGNYL. (chorionic gonadotropin for injection, USP) 10,000 units/vial. Human Gonadotropin PACKAGE INSERT PREGNYL (chorionic gonadotropin for injection, USP) 10,000 units/vial Human Gonadotropin Merck Canada Inc. 16750 route Transcanadienne Kirkland QC Canada H9H 4M7 Date of Revision: February

More information

Metformin treatment before IVF / ICSI in non obese PCOS women

Metformin treatment before IVF / ICSI in non obese PCOS women Metformin treatment before IVF / ICSI in non obese PCOS women A Nordic, prospective, randomised, double blind, multicentre study Sigrun Kjøtrød University Hospital of Trondheim, Norway Metformin effects

More information

Abnormal Uterine Bleeding FAQ Sheet

Abnormal Uterine Bleeding FAQ Sheet Abnormal Uterine Bleeding FAQ Sheet What is abnormal uterine bleeding? Under normal circumstances, a woman's uterus sheds a limited amount of blood during each menstrual period. Bleeding that occurs between

More information

Strategies and the Nursing Care Management of Adolescents Diagnosed with PCOS. Conflicts of Interest. Objectives. None Phaedra Thomas 4/23/2015

Strategies and the Nursing Care Management of Adolescents Diagnosed with PCOS. Conflicts of Interest. Objectives. None Phaedra Thomas 4/23/2015 Strategies and the Nursing Care Management of Adolescents Diagnosed with PCOS Phaedra Thomas, RN BSN Co-Director and Nurse Educator Center for Young Women s Health Boston Children s Hospital youngwomenshealth.org

More information

Clinical Study Comparison of IVF Outcomes between Minimal Stimulation and High-Dose Stimulation for Patients with Poor Ovarian Reserve

Clinical Study Comparison of IVF Outcomes between Minimal Stimulation and High-Dose Stimulation for Patients with Poor Ovarian Reserve International Reproductive Medicine, Article ID 581451, 5 pages http://dx.doi.org/10.1155/2014/581451 Clinical Study Comparison of IVF Outcomes between Minimal Stimulation and High-Dose Stimulation for

More information

WOMENCARE A Healthy Woman is a Powerful Woman (407) 898-1500. Endometriosis

WOMENCARE A Healthy Woman is a Powerful Woman (407) 898-1500. Endometriosis Endometriosis WOMENCARE A Healthy Woman is a Powerful Woman (407) 898-1500 The lining of the uterus is called the endometrium. Sometimes, endometrial tissue grows elsewhere in the body. When this happens

More information

Testosterone for women, who when and how much?

Testosterone for women, who when and how much? Medicine, Nursing and Health Sciences Testosterone for women, who when and how much? Susan R Davis MBBS FRACP PhD Women s Health Research Program School of Public Health Monash University Melbourne Medicine,

More information

Polycystic Ovary Syndrome: Diagnosis and Treatment

Polycystic Ovary Syndrome: Diagnosis and Treatment The American Journal of Medicine (2007) 120, 128-132 UPDATE IN OFFICE MANAGEMENT Polycystic Ovary Syndrome: Diagnosis and Treatment Tracy L. Setji, MD, Ann J. Brown, MD, MHS Department of Medicine, Division

More information

The causes of infertility include abnormalities of any portion of the male or female reproductive system.

The causes of infertility include abnormalities of any portion of the male or female reproductive system. Harvard-MIT Division of Health Sciences and Technology HST.071: Human Reproductive Biology Course Director: Professor Henry Klapholz IN SUMMARY Defined as 1 year of unprotected intercourse during which

More information

Fertility Preservation in Women with Cancer. Objectives. Patient #1 10/24/2011. The audience will understand: How cancer therapy affects fertility.

Fertility Preservation in Women with Cancer. Objectives. Patient #1 10/24/2011. The audience will understand: How cancer therapy affects fertility. Fertility Preservation in Women with Cancer Leslie R. DeMars Dartmouth-Hitchcock Medical Center Objectives The audience will understand: How cancer therapy affects fertility. Who should be considered for

More information

Age and Fertility. A Guide for Patients PATIENT INFORMATION SERIES

Age and Fertility. A Guide for Patients PATIENT INFORMATION SERIES Age and Fertility A Guide for Patients PATIENT INFORMATION SERIES Published by the American Society for Reproductive Medicine under the direction of the Patient Education Committee and the Publications

More information

The Outcome of Repeated In Vitro Fertilization-Embryo Transfer Based on the Endometrial Thickness

The Outcome of Repeated In Vitro Fertilization-Embryo Transfer Based on the Endometrial Thickness Bulletin of the Osaka Medical College 49 1, 2 5-9, 2003 5 Original Article The Outcome of Repeated In Vitro Fertilization-Embryo Transfer Based on the Endometrial Thickness Yoshiki YAMASHITA, Toshimitsu

More information

Improvement in diagnostic performance of the revised total testosterone measuring system in Japanese women with polycystic ovary syndrome

Improvement in diagnostic performance of the revised total testosterone measuring system in Japanese women with polycystic ovary syndrome 65 ORIGINAL Improvement in diagnostic performance of the revised total testosterone measuring system in Japanese women with polycystic ovary syndrome Hirobumi Niki, Toshiya Matsuzaki, Riyo Kinouchi, Takeshi

More information

Acupuncture Treatment For Infertile Women Undergoing Intracytoplasmic Sperm injection

Acupuncture Treatment For Infertile Women Undergoing Intracytoplasmic Sperm injection Acupuncture Treatment For Infertile Women Undergoing Intracytoplasmic Sperm injection Sandra L. Emmons, MD Phillip Patton, MD Source: Medical Acupuncture, A Journal For Physicians By Physicians Spring

More information

HOW IS OVARIAN RESERVE ASSESSED?

HOW IS OVARIAN RESERVE ASSESSED? HOW IS OVARIAN RESERVE ASSESSED? The majority of indicators we have to assess OR assess egg quantity rather than egg quality and these two do not always go hand in hand. No individual test is a perfect

More information

Body Mass Index and Gonadotropin Hormones (LH & FSH) Associate With Clinical Symptoms Among Women With Polycystic Ovary Syndrome

Body Mass Index and Gonadotropin Hormones (LH & FSH) Associate With Clinical Symptoms Among Women With Polycystic Ovary Syndrome Global Journal of Health Science; Vol. 7, No. 2; 2015 ISSN 1916-9736 E-ISSN 1916-9744 Published by Canadian Center of Science and Education Body Mass Index and Gonadotropin Hormones (LH & FSH) Associate

More information

Abnormal Uterine Bleeding: Simple evaluation and management in premenopausal women

Abnormal Uterine Bleeding: Simple evaluation and management in premenopausal women Objectives Abnormal Uterine Bleeding: Simple evaluation and management in premenopausal women Provide a framework to evaluate abnormal uterine bleeding (AUB) Review medical and surgical management options

More information

SPONTANEOUS AND PHARMACOLOGICALLY INDUCED REMISSIONS IN PATIENTS WITH PREMATURE OVARIAN FAILURE

SPONTANEOUS AND PHARMACOLOGICALLY INDUCED REMISSIONS IN PATIENTS WITH PREMATURE OVARIAN FAILURE SPONTANEOUS AND PHARMACOLOGICALLY INDUCED REMISSIONS IN PATIENTS WITH PREMATURE OVARIAN FAILURE David Kreiner, M. D. * Kathleen Droesch, M.D. Daniel Navot, M.D. Richard Scott, M.D. Zev Rosenwaks, M.D.

More information

Systematic review by: Dr. Ashraf Ahmed ElDaly, M.Sc., M.D.

Systematic review by: Dr. Ashraf Ahmed ElDaly, M.Sc., M.D. Role of luteinizing hormone supplementation in the follicular phase and pregnancy, during controlled ovarian hyperstimulation in in vitro fertilization Systematic review by: Dr. Ashraf Ahmed ElDaly, M.Sc.,

More information

OVARIAN CYSTS. Types of Ovarian Cysts There are many types of ovarian cysts and these can be categorized into functional and nonfunctional

OVARIAN CYSTS. Types of Ovarian Cysts There are many types of ovarian cysts and these can be categorized into functional and nonfunctional OVARIAN CYSTS Follicular Cyst Ovarian cysts are fluid-filled sacs that form within or on the ovary. The majority of these cysts are functional meaning they usually form during a normal menstrual cycle.

More information

FERTILITY AND AGE. Introduction. Fertility in the later 30's and 40's. Am I fertile?

FERTILITY AND AGE. Introduction. Fertility in the later 30's and 40's. Am I fertile? FERTILITY AND AGE Introduction Delaying pregnancy is a common choice for women in today's society. The number of women in their late 30s and 40s attempting pregnancy and having babies has increased in

More information

Director, IVF Program, Division of Reproductive Endocrinology & Infertility

Director, IVF Program, Division of Reproductive Endocrinology & Infertility Director, IVF Program, Division of Reproductive Endocrinology & Infertility Date: January 17, 2006 To: From: RE: All IVF candidates Chief, Reproductive Endocrinology & Infertility Criteria for IVF program

More information

MECHANISM OF ACTION. Fertility Awareness-Based Methods. Victoria H. Jennings, PhD Marcos Arevalo, MD, MPH Deborah Kowal, MA, PA

MECHANISM OF ACTION. Fertility Awareness-Based Methods. Victoria H. Jennings, PhD Marcos Arevalo, MD, MPH Deborah Kowal, MA, PA Fertility Awareness-Based Methods Victoria H. Jennings, PhD Marcos Arevalo, MD, MPH Deborah Kowal, MA, PA Fertility awareness helps couples understand how to avoid pregnancy or how to become pregnant.

More information

Management fertility sparing degli endometriomi Errico Zupi

Management fertility sparing degli endometriomi Errico Zupi Management fertility sparing degli endometriomi Errico Zupi Università Tor Vergata Roma Management of endometrioma Pain Infertility Surgical treatment Medical treatment Infertility clinic Both medical

More information

Sponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.

Sponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational. Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,

More information

The PCOS - Diabetes Connection

The PCOS - Diabetes Connection PCOS Awareness Symposium 2015 Philadelphia Saturday, April 18 th, 2015 The PCOS - Diabetes Connection Preventing Stroke, Kidney Disease, Liver Disease & Other Complications Katherine Sherif, MD Professor

More information

Polycystic ovarian syndrome in women with acne

Polycystic ovarian syndrome in women with acne Original Article Polycystic ovarian syndrome in women with acne Sayera Begum*, M Zakir Hossain**, Md. Fashiur Rahman, Laila Anjuman Banu *Department of Dermatology & Venereology, Central Police Hospital,

More information

GP tool. Polycystic ovary syndrome

GP tool. Polycystic ovary syndrome Polycystic ovary syndrome GP tool This resource is informed by the evidence-based guideline for the assessment and management of polycystic ovary syndrome (PCOS), authored by the PCOS Australian Alliance

More information

Fast Track to IVF. Objectives

Fast Track to IVF. Objectives Disclosure statement: Richard H. Reindollar, M.D. has no relevant financial relationships with any manufacturers of pharmaceuticals, laboratory supplies, or medical devices. Fast Track to IVF Richard H.

More information

OVARIAN CYSTS AND TORSION

OVARIAN CYSTS AND TORSION Key: = important notes = reference to torsion = reference to malignancy OVARIAN CYSTS AND TORSION Epidemiology:

More information

Abnormal Uterine Bleeding

Abnormal Uterine Bleeding Abnormal Uterine Bleeding WOMENCARE A Healthy Woman is a Powerful Woman (407) 898-1500 Abnormal uterine bleeding is one of the most common reasons women see their doctors. It can occur at any age and has

More information